Lung Cancers Completed Phase 1 / 2 Trials for Erlotinib (DB00530)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01068587MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous ChemotherapyTreatment
NCT02155465Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibTreatment
NCT00390429Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTreatment
NCT01302808Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerTreatment
NCT00826449Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT00387322Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTreatment
NCT00280150Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung CancerTreatment
NCT00043823Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung CancerTreatment